Evidence map›Paper›PMID 39906487›Full record

ArticleFrontiers in molecular biosciences2024

Detection of fusion events by RNA sequencing in FFPE versus freshly frozen colorectal cancer tissue samples.

Maxim Sorokin, Vladimir Lyadov, Maria Suntsova, Marat Garipov, Anna Semenova, Natalia Popova, Egor Guguchkin, Rustam Heydarov, Marianna Zolotovskaia, Xiaowen Zhao and 4 more

Abstract read
In one paragraph

Article in Frontiers in molecular biosciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. AccurateInternational journal of molecular sciences · 2025
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Maxim SorokinOmicsWay Corp., Covina, CA, United States.
Vladimir LyadovMoscow State Budgetary Healthcare Institution "Moscow City Oncological Hospital N1, Moscow Healthcare Department", Moscow, Russia.
Maria SuntsovaInstitute of Personalized Oncology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
Marat GaripovMoscow State Budgetary Healthcare Institution "Moscow City Oncological Hospital N1, Moscow Healthcare Department", Moscow, Russia.
Anna SemenovaMoscow State Budgetary Healthcare Institution "Moscow City Oncological Hospital N1, Moscow Healthcare Department", Moscow, Russia.
Natalia PopovaMoscow State Budgetary Healthcare Institution "Moscow City Oncological Hospital N1, Moscow Healthcare Department", Moscow, Russia.
Egor GuguchkinInstitute for System Programming of RAS, Moscow, Russia.
Rustam HeydarovInstitute of Personalized Oncology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
Marianna ZolotovskaiaMoscow Center for Advanced Studies, Moscow, Russia.
Xiaowen ZhaoCore lab, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, China.
Qing YanCore lab, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, China.
Ye WangCore lab, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, China.
Evgeny KarpulevichInstitute for System Programming of RAS, Moscow, Russia.
Anton BuzdinPathoBiology Group, European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gene fusion events result in chimeric proteins that are frequently found in human cancers. Specific targeted therapies are available for several types of cancer fusions including receptor tyrosine kinase gene moieties. RNA sequencing (RNAseq) can directly be used for detection of gene rearrangements in a single test, along with multiple additional biomarkers. However, tumor biosamples are usually formalin-fixed paraffin-embedded (FFPE) tissue blocks where RNA is heavily degraded, which in theory may result in decreased efficiency of fusion detection. Here, for the first time, we compared the efficacy of gene fusion detection by RNAseq for matched pairs of freshly frozen in RNA stabilizing solution (FF) and FFPE tumor tissue samples obtained from 29 human colorectal cancer patients. We detected no statistically significant difference in the number of chimeric transcripts in FFPE and FF RNAseq profiles. The known fusion

Indexed as

chimeric transcriptscolorectal cancerdetection of gene rearrangementsFFPEformalin-fixed paraffin-embedded tumor tissue samplesnew cancer fusion genesRNAseqRNA sequencing

Identifiers

PMID39906487
PMCPMC11791353

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.